AUTHORS
Jian Huang, MD, PhD, Zhikang Zheng2, Tian Zeng3, Rumeng Li4, Qingmei Han5, Bingbing Wen6
AFFILIATIONS
1 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
2 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
3 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
4 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
5 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
6 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
ABSTRACT
Introduction: Bone marrow morphology plays a central role in the diagnosis of essential thrombocythemia (ET), with megakaryocyte (MK) morphology serving as a key distinguishing feature. The typical bone marrow findings in ET include increased numbers of MKs, which are loosely clustered, large in size, hyperlobulated(staghorn like), abnormal N:C ratio, and relatively mature in appearance. However, in clinical practice, varying degrees of dysplastic MK changes—such as hyperchromatic nuclei, micromegakaryocytes, bizarre-shaped forms, and even myelodysplastic syndrome (MDS)-like separated nuclear or hypolobated/non-lobated megakaryocytes—are occasionally observed in a subset of ET patients. Whether this morphological heterogeneity reflects distinct underlying disease biology remains largely unexplored. Previous studies have suggested that certain MK subtypes may correlate with the risk of disease transformation; however, the impact of MK morphological heterogeneity on long-term survival and prognosis in ET remains poorly defined. Therefore, the aim of this study was to quantitatively analyze the proportions of different MK morphological variants in order to accurately assess the risk of disease progression.
Methods: We retrospectively reviewed bone marrow smears from 222 patients with essential thrombocythemia (ET) diagnosed at the First Affiliated Hospital of Zhejiang University and the Fourth Affiliated Hospital of Zhejiang University between October 2012 and May 2026. A total of 19,211 MKs were manually counted under light microscopy. For survival analysis, progression free survival (PFS) curves were constructed using the Kaplan-Meier method, and differences between groups were compared using the log rank test. To identify prognostic factors, univariate and multivariate Cox proportional hazards regression models were applied. Moreover, the cut-off point for risk stratification was selected via the “Surv_cutpoint” function from survival package in R.
Results: Among the 222 patients with ET, 46% were male and 54% were female, with a median age of 55 years (range, 18–85 years). Follow up data were available for 159 patients, with a median follow up duration of 48 months (interquartile range, 28–72 months). The overall 5 year PFS rate was 90.15% (95%CI, 84.76%–95.87%). Disease progression occurred in 16 patients (10%), including 15 cases of transformation to myelofibrosis(MF) and 1 case of transformation to acute myeloid leukemia(AML).
Subgroup analyses revealed that the 5 year PFS rate was significantly higher in patients with a normal MK proportion ≥66% than in those with <66% [96.67% (95% CI: 90.45%–100.00%) vs. 86.20% (95% CI: 78.66%–94.46%), P = 0.0124]; higher in the staghorn like MK <6% group than in the ≥6% group [95.52% (95% CI: 89.49%–100.00%) vs. 85.20% (95% CI: 76.85%–94.47%), P = 0.0139]; higher in the Naked nuclei <9% group than in the ≥9% group [94.12% (95% CI: 89.02%–99.51%) vs. 76.10% (95% CI: 61.67%–93.92%), P = 0.0002]; and higher in the separated nuclear <3% group than in the ≥3% group [94.62% (95% CI: 89.43%–100.00%) vs. 82.54% (95% CI: 71.78%–94.92%), P = 0.0029].
Univariate and multivariate analyses identified Naked nuclei (HR = 1.09, 95% CI: 1.03–1.16, P = 0.006) and separated nuclear (HR = 1.09, 95% CI: 1.00–1.17, P = 0.041) as independent adverse prognostic factors for overall survival (OS), while normal MK proportion (HR = 0.97, 95% CI: 0.94–1.00, P = 0.044) was a protective factor.
Heatmap analysis suggested significant heterogeneity in MK morphology among ET patients, with clustering and synergistic aggregation among abnormal morphological parameters.
Conclusion: The 5 year PFS rate in ET patients is relatively high. Increased proportions of abnormal MK morphologies, such as Naked nuclei and separated nuclear, are associated with poor prognosis, whereas a higher proportion of normal MKs serves as a protective factor. Quantitative MK morphological parameters may provide references for prognostic stratification in ET, although external validation is warranted.
Achnowledgement: This research was supported by the National Natural Science Foundation of China (No. 82570191) and the Zhejiang Provincial Health Highlevel Innovative Talent Project (2022-2026).
*Correspondence to: Jian Huang, M.D., Ph.D., Department of Hematology, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang, China. E-mail: househuang@zju.edu.cn
DISCLOSURES
Jian Huang, MD, PhD: No relevant conflicts of interest to declare.